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Abstract PDE4 isoenzymes are critical in the control of
cAMP signaling in rodent cardiac myocytes. Ablation of
PDE4 affects multiple key players in excitation–contraction
coupling and predisposes mice to the development of heart
failure. As little is known about PDE4 in human heart, we
explored to what extent cardiac expression and functions of
PDE4 are conserved between rodents and humans. We find
considerable similarities including comparable amounts of
PDE4 activity expressed, expression of the same PDE4
subtypes and splicing variants, anchoring of PDE4 to the
same subcellular compartments and macromolecular sig-
naling complexes, and downregulation of PDE4 activity and
protein in heart failure. The major difference between the
species is a fivefold higher amount of non-PDE4 activity in
human hearts compared to rodents. As a consequence, the
effect of PDE4 inactivation is different in rodents and
humans. PDE4 inhibition leads to increased phosphorylation
of virtually all PKA substrates in mouse cardiomyocytes, but
increased phosphorylation of only a restricted number of
proteins in human cardiomyocytes. Our findings suggest that
PDE4s have a similar role in the local regulation of cAMP
signaling in rodent and human heart. However, inhibition of
PDE4 has ‘global’ effects on cAMP signaling only in rodent
hearts, as PDE4 comprises a large fraction of the total cardiac
PDE activity in rodents but not in humans. These differences
may explain the distinct pharmacological effects of PDE4
inhibition in rodent and human hearts.
Keywords cAMP  30,50-Cyclic nucleotide
phosphodiesterase  PDE4  Human heart  Heart failure
Abbreviations
bAR b-Adrenoceptor
Cav1.2 L-type calcium channel
DHCM Dividing human cardiomyocytes
GPCR G protein-coupled receptor
IDC Idiopathic dilated cardiomyopathy
IP Immunoprecipitation
ISO Isoproterenol
PDE 30,50-Cyclic nucleotide phosphodiesterase
PKA cAMP-dependent protein kinase
PLB Phospholamban
RyR2 Ryanodine receptor
SERCA Sarcoendoplasmic reticulum calcium ATPase
Introduction
cAMP is a ubiquitous second messenger that transduces the
action of numerous hormones and neurotransmitters into
cellular responses. In the heart, cAMP mediates the ino-
tropic, chronotropic and lusitropic effects of b-adrenoceptor
(bAR) stimulation by catecholamines, as well as the effects
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of many other hormones that act through G protein-coupled
receptors (GPCRs), including prostaglandins, glucagon and
serotonin [42, 65, 66, 83, 85].
In order to maintain the specificity of the diverse hormone
responses, cAMP signaling is compartmentalized [43, 49].
Proteins involved in cAMP signaling, such as GPCRs,
adenylyl cyclases and cAMP effectors such as the cAMP-
dependent protein kinase (PKA) and its downstream targets,
are organized into physically and functionally distinct multi-
protein complexes, an arrangement that increases both effi-
ciency and specificity of signaling. Cyclic nucleotide
phosphodiesterases (PDEs), the enzymes that hydrolyze and
inactivate cAMP, are critical components of these signaling
complexes, serving to limit access to and to finely regulate
cAMP levels within these compartments [9]. Eleven families
of phosphodiesterases, defined based on their kinetic and
pharmacologic properties, have been identified [9]. The
enzymes belonging to the PDE4 family are particularly
important in the control of cAMP signaling in rodent cardiac
myocytes. PDE4 isoforms control the PKA-mediated regu-
lation of b1- and b2ARs, L-type calcium channels (Cav1.2),
cardiac ryanodine receptors (RyR2), the phospholamban/
sarcoplasmic reticulum calcium ATPase (PLB/SERCA)
complex and troponin I [19, 26, 35, 39, 41, 58, 63, 84].
Several of these signaling proteins have been shown to anchor
PDE4 isoenzymes in signaling complexes.
The PDE4 family consists of four genes, PDE4A to
PDE4D. By the use of different promoters and alternative
splicing, each PDE4 gene is expressed as multiple variants.
Together, more than 20 PDE4 variants are known. They differ
in their regulatory properties and their subcellular localiza-
tion, which is determined by variant-specific protein/protein
or protein/lipid interactions [10, 25]. The observation that the
various signaling complexes identified in the heart exhibit a
distinct preference for one particular PDE4 variant or another
suggests that individual PDE4 variants serve unique func-
tions. b1AR, b2AR, and RyR2, for example, interact prefer-
entially with the variants PDE4D8, PDE4D5, and PDE4D3,
respectively [39, 58, 63]. PDE4 inhibition often substantially
increases their PKA-dependent phosphorylation, and thereby
exerts a considerable impact on the function of the associated
signaling proteins in isolated cardiomyocytes in culture
[11, 50, 65, 84], though the effects of acute PDE4 inhibition
on cardiac performance in live animals are often subtle. PDE4
inactivation has been reported to produce a small effect
on basal blood pressure and heart rate or b-adrenoceptor-
stimulated heart rate in animals in some studies but to have no
effect in others [20–22, 34, 54, 61, 73, 82]. In addition, PDE4
inactivation generally does not affect inotropy under basal
conditions. However, PDE4 inactivation has been shown to
potentiate the inotropic responses of cardiac tissue prepara-
tions to serotonin, glucagon, catecholamines or PDE3
inhibitors in mouse, rat, guinea pig, rabbit and dog ex vivo
suggesting that PDE4 is more critical under conditions of
elevated cAMP production [7, 15, 16, 22, 29, 32, 34, 54, 68,
77, 82]; see [57] for a review.
The limited effects of PDE4 inactivation on cardiac
function may attest to the capacity of the mammalian
organism to compensate for loss of PDE4. It is also possible
that PDE4 inactivation in different intracellular compart-
ments may have opposing effects on cardiac performance.
Whereas increased PKA phosphorylation of Cav1.2, PLB or
RyR2 resulting from PDE4 ablation may increase excita-
tion–contraction coupling and cardiac output, the effect of
increased phosphorylation of bARs, troponin I and perhaps
other PKA substrates could counteract these effects [63].
Thus, the outcome of cAMP elevation triggered by the
activation of cAMP production (such as through b-adrener-
gic stimulation) is functionally distinct from cAMP elevation
resulting from PDE4 inactivation. The overall effect of
PDE4 inactivation is not an increase in cardiac output per se.
Instead, PDE4 inactivation likely removes a compensatory
mechanism that normally allows cardiac myocytes to finely
tune cAMP levels in different subcellular compartments. As
a result, PDE4 inactivation may result in adverse cardiac
effects that are uncovered under stress conditions. Pharma-
cologic or genetic inactivation of PDE4 potentiates adrena-
lin-evoked [13] or exercise-induced [39] arrhythmias in
mice, and PDE4 inhibition triggers arrhythmias in a coronary
artery occlusion and reperfusion model in rabbits [24]. In
addition, genetic inactivation of PDE4D in mice triggers
development of a late-onset cardiomyopathy and increased
mortality after cardiac infarction [39].
Whereas much has been learned about the unique roles
of PDE4 isoenzymes in cardiac physiology and patho-
physiology in experimental animals, little is known about
the role of PDE4 in the human heart. With respect to at
least one other phosphodiesterase, PDE5, marked differ-
ences in expression between mouse and human hearts have
been reported [75], thus raising questions regarding the
applicability of the mouse model to pathophysiology and
therapeutics in humans [38, 45, 60, 75]. We, therefore,
examined the expression patterns of PDE4 variants in the
hearts of mice, rats, and humans, their subcellular targeting
and changes in expression levels between healthy and
failing hearts as well as the effect of PDE4 inactivation on
PKA-mediated phosphorylation patterns.
Methods
Heart tissue
Human myocardium was obtained from the left ventricular
free walls of the hearts of organ donors for whom no
suitable recipients were identified on the United Network
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for Organ Sharing (UNOS) waiting list at the time of organ
procurement (‘normal’ hearts) and of the explanted hearts
of patients with idiopathic dilated cardiomyopathy (IDC)
undergoing cardiac transplantation (failing hearts) as
described previously [52]. The use of human tissues was
approved by the University of Utah internal review board
and conformed to the principles outlined in the 1964
Declaration of Helsinki. All animal studies were performed
according to the guidelines of the National Institutes of
Health Guide for the Care and Use of Laboratory Animals
published by the US National Institutes of Health (NIH
Publication No. 85-23, revised 1996) and were approved by
the Institutional Animal Care and Use Committee of the
University of California San Francisco.
Immunoprecipitation
Heart tissues were homogenized in 50 mM Tris–HCl (pH
7.4), 1 mM EDTA, 0.2 mM EGTA, 150 mM NaCl,
1.34 mM b-mercaptoethanol, 10% glycerol, 0.2% NP-40
(nonylphenoxypolyethoxylethanol), 1 lM microcystin-LR,
Complete protease inhibitor cocktail (Roche Diagnostics),
and 1 mM AEBSF (4-(2-aminoethyl)-benzenesulfonyl
fluoride hydrochloride). Extracts were precleared with 50 ll
ProteinG-Sepharose for 1 h, followed by immunoprecipita-
tion with 30 ll ProteinG-Sepharose and 2 lg of the respec-
tive antibody for 4 h.
Cell culture
Dividing human cardiomyocytes (DHCMs) were obtained
from PromoCell GmbH and cultured in PromoCell’s Myo-
cyte Growth Medium. Ventricular cardiomyocytes were
isolated from the excised hearts of 1–2-day-old neonatal mice
and subsequently cultured as described previously [63].
PDE activity assay
PDE activity was measured using 1 lM cAMP as substrate as
described previously [63]. The activity forPDE1, PDE2, PDE3
and PDE4 was defined as the fraction of total PDE activity
inhibited by vinpocetine (20 lM), Bay 60-7550 (100 nM),
cilostamide (1 lM) and rolipram (10 lM), respectively.
Adenylyl cyclase activity assay
Adenylyl cyclase activity was measured as described pre-
viously [28].
Antibodies
The following antibodies were used: rabbit anti-sarcomeric
actinin (Abcam), calsequestrin and phospholamban
(Affinity BioReagents), PKA substrate (Cell Signaling),
Ser16-phospho-phospholamban (Upstate), b1AR (Santa
Cruz Biotechnology), mouse anti-sarcomeric actinin, anti-
Flag and a-tubulin (Sigma-Aldrich), antibodies against
individual PDE4A and PDE4B variants (Fabgennix),
PDE4D (ICOS). PAN-PDE4 as well as PDE4 subtype- and
splice variant-selective antibodies have been described
previously [64].
Immunocytochemistry
Human or mouse myocardium was frozen in Tissue-Tek
O.C.T. (Optimal Cutting Temperature) Compound (Sakura
Finetek) and sectioned at 7 lm. Slides were fixed with 4%
paraformaldehyde for 20 min followed by a 5-min incu-
bation with 0.5% Triton X-100 in PBS. Slides were
blocked for 60 min at room temperature with PBS con-
taining 10% goat serum, 1% BSA, and 0.1% Triton X-100.
Slides were then incubated for 2 h with primary antibodies
diluted 1:500 in blocking buffer. After three washes with
blocking buffer, the sections were incubated for 1 h with
fluorescein isothiocyanate (FITC)-labeled and Cy3-labeled
secondary antibodies, washed three times with blocking
buffer and mounted in VectaShield mounting medium
(Vector Laboratories).
Detailed methods are included in the supplementary
material.
Results
A conserved expression pattern of PDE4 subtypes
and variants detected in human and rodent myocardium
As the first step in exploring the role of PDE4 in the human
heart, we compared levels of PDE4 activity in preparations of
human left ventricular myocardium and in comparable
preparations from mouse and rat hearts. When normalized to
total protein, PDE4 activity was present at similar levels of
17–24 pmol/min/mg protein in mouse, rat and human heart
(Fig. 1a). There were major differences, however, in the
levels of PDE4 activity relative to total cellular phospho-
diesterase activity. PDE4 contributes a much larger portion of
the total PDE activity in mouse and rat heart (32 and 52%,
respectively) than in human heart (8%) (Fig. 1b). This dif-
ference is attributable to the fivefold higher total cAMP-
hydrolytic activity in humans relative to rodents, which
results from the high level expression of several non-PDE4
subtypes, including PDE1, PDE2 and PDE3, in humans. The
higher amount of total PDE activity present in human heart
compared to rodents is not accompanied by a similarly higher
level of adenylyl cyclase activity (Supplementary Fig. 1). As
a result, there is a higher ratio of cAMP-hydrolytic activity to
Basic Res Cardiol (2011) 106:249–262 251
123
total cAMP-generating activity in human hearts compared to
rodent hearts.
Next, we determined the intracellular localization of
PDE4 in cardiac muscle by immunocytochemistry. PDE4
localizes to the Z-band of cardiomyocytes in human
(Fig. 1c) and mouse heart (data not shown), suggesting that
PDE4 activity detected in heart extracts is due to the
expression of PDE4 in the cardiomyocytes and that PDE4
acts in defined subcellular compartments of these cells.
These observations, which may suggest a conservation of
PDE4 function between these species, led us to investigate
patterns of PDE4 expression, localization, and function in
more detail in rodent and human heart. To determine the
contribution of the different PDE4 subtypes to the total
PDE4 activity expressed, we performed immunoprecipita-
tions (IPs) with PDE4 subtype-selective antibodies fol-
lowed by measurement of PDE activity in the IP pellets.
The specificity of these antibodies for the targeted PDE4
subtypes was confirmed in experiments using preparations
from the respective knock-out mice (Supplementary
Fig. 2). Using this approach, three PDE4 subtypes, PDE4A,
PDE4B and PDE4D, could be immunoprecipitated from
preparations of mouse, rat and human hearts (Fig. 2). Ear-
lier reports suggested that PDE4C mRNA and protein is not
expressed in the heart [37]; thus, PDE4C was not investi-
gated. PDE4A, PDE4B and PDE4D are expressed at com-
parable levels in rodents, whereas PDE4D appears to be the
predominant form expressed in human heart.
Each of the four PDE4 genes is expressed as multiple
variants. As individual variants are thought to have specific
roles in a cell, we wished to determine whether the same
PDE4 variants are expressed in the hearts of mice, rats and
humans. A predominant band for PDE4A, migrating at
105–110 kDa, was identified in mouse hearts (Fig. 3a, top
left panel). The majority of this band is attributable to
PDE4A10, whereas a small fraction is due to PDE4A5, as
determined by migration of this band in SDS/PAGE and
pull-down experiments with PDE4A variant-selective
antibodies (Supplementary Fig. 3). This finding is consis-
tent with reports that mRNA for PDE4A10 is found at high
levels in the heart [62]. An immunoreactive band consistent
with the migration of PDE4A10 was similarly detected in
A B
Mouse Rat Human
0
20
40
60
80
100
Total
non-PDE4
PDE4
PD
E 
ac
tiv
ity
(%
 of
 to
tal
)
Total PDE1 PDE2 PDE3 PDE4
0
50
100
150
200
250
300
Mouse
Rat
Human
PDE
PD
E 
ac
tiv
ity
(p
mo
l/m
in/
mg
 pr
ot
ein
)
C normal rabbit serum                 anti-PAN-PDE4   
anti-sarcomeric actinin
merge
Fig. 1 Expression of PDE
subtypes in mouse, rat and
human heart. Detergent extracts
prepared from mouse, rat or
failing human hearts were
subjected to PDE activity assays
in the presence or absence of
subtype-selective PDE
inhibitors using 1 lM cAMP as
substrate. Total PDE activity is
defined as the activity measured
in the absence of inhibitors,
whereas PDE1, PDE2, PDE3
and PDE4 are defined as the
fraction of total PDE activity
inhibited by vinpocetine
(20 lM), Bay 60-7550 (100
nM), cilostamide (1 lM) and
rolipram (10 lM), respectively.
Data are presented as specific
PDE activity in pmol/min/mg in
(a) and as % of total activity in
(b) and represent the
mean ± SEM of four
experiments. c Cryosections of
human myocardium were
double-stained with antibodies
against sarcomeric actinin (red)
and either anti-PAN-PDE4
antibodies or normal IgG as a
control (green)
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rat and human heart suggesting that PDE4A10 is the pre-
dominant PDE4A variant expressed in all three species
(Fig. 3a, top panels).
A similar picture emerged when comparing the PDE4B
immunoblot signals (Fig. 3a, middle panels). A major
signal for PDE4B is detected at *95 kDa in mouse heart,
and immunoreactive bands of the same migration were
found in rat and human tissue. Migration of the PDE4B
band detected in heart tissues is consistent with that of
recombinant PDE4B3 and the expression of PDE4B3 in
heart tissue was confirmed with variant-selective antibod-
ies (Supplementary Fig. 4).
Finally, for PDE4D, a similar pattern of immunoblot
signals was detected in the three species (Fig. 3a, bottom
panels). A predominant band is detected at 91–95 kDa,
consistent with the migration of PDE4D3, PDE4D8, or
PDE4D9 [64]. Upon longer exposure of the blots, a minor
band of higher molecular weight is detected. Its migration
corresponds to that of PDE4D5 or PDE4D7 [64]. To dis-
tinguish between the variants of similar migration, we
carried out immunoprecipitations with splice variant-
selective antibodies. As shown in Fig. 3b, PDE4D3,
PDE4D5, PDE4D8 and PDE4D9, but not PDE4D4, are
detected in mouse, rat and human heart (top, middle and
bottom panels). Both the similar pattern of immunoreactive
bands for PDE4A, PDE4B and PDE4D in SDS/PAGE
(Fig. 3a) as well as the expression of similar PDE4 variants
as detected by immunoprecipitations (Supplementary
Figs. 3 and 4, and Fig. 3b) suggest that the same splice
variants of PDE4 are expressed in mouse, rat and human
heart.
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Fig. 2 Expression of PDE4 subtypes in rodent and human heart.
Detergent extracts prepared from mouse, rat or failing human hearts
were subjected to immunoprecipitations with PDE4 subtype-selective
antibodies or normal IgG as a control. PDEs recovered in the IP pellet
were detected by PDE activity assay using 1 lM cAMP as substrate.
Data are presented as mean ± SEM of at least three experiments. n.s.
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Fig. 3 Expression of PDE4 splice variants in rodent and human
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control or a PDE4 subtype-selective or b PDE4D variant-selective
antibodies. PDE4 proteins recovered in the IP pellets were detected by
Western blotting using PAN-PDE4 antibodies. All Western blots
shown are representative of experiments performed three times
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Detection of macromolecular signaling complexes
involving PDE4 in the human heart
Individual PDE4 variants are often engaged in unique mac-
romolecular signaling complexes. Having found similar
patterns of expression of PDE4 isoforms and variants in
rodent and human hearts, we tested whether these variants are
localized to the same macromolecular signaling complexes.
A complex formed between the b1AR and PDE4D has been
reported in mouse cardiac myocytes [63]. As shown in Fig. 4,
the only cAMP-hydrolytic activity specifically co-immuno-
precipitated with an antibody against the endogenous b1AR
from human myocardium is PDE4 (see Supplementary
Fig. 5 for a characterization of the b1AR antibody used). This
suggests that PDE4, while representing only a small fraction
of total cAMP-hydrolytic activity in human myocardium,
may have a predominant role in regulating cAMP content in
the vicinity of the b1AR. As a second target, we investigated
the PLB/SERCA2 signaling complex, which has been shown
to bind PDE4D in mouse heart [35]. Immunoprecipitations
using an anti-PLB antibody pull down a significant amount
of PDE activity from human heart extracts, indicating
that PDEs are localized to this complex as well (Fig. 4b).
Approximately half of the cAMP-hydrolytic activity that
co-immunoprecipitates with phospholamban is PDE4, sug-
gesting that it is one of several phosphodiesterases that
regulate cAMP content in this compartment. Its presence in
defined signaling complexes suggests that PDE4 is likely to
serve similar functions in controlling cAMP signaling in
discrete microdomains, such as in the vicinity of the b1AR as
well as PLB in both rodents and humans. The presence of
PDE4 in these signaling complexes is also in agreement with
its subcellular localization to the Z-band of human cardio-
myocytes as shown in Fig. 1c.
PDE4 expression is reduced in failing human heart
A recent report demonstrated reduced levels of PDE4
activity and protein in a rat model of cardiac hypertrophy
[1]. We wished to determine if similar differences exist
between normal and failing human heart. In agreement
with previous reports, we found no difference in total PDE
activity between extracts prepared from normal hearts and
the explanted hearts from patients with idiopathic dilated
cardiomyopathy (IDC) (Fig. 5a) [3, 53, 57, 71, 75, 78].
Next, we determined the levels of PDE4 subtypes by
immunoprecipitation with subtype-selective antibodies. As
shown in Fig. 5b and c, activities for PDE4A and PDE4D
were significantly lower in failing hearts compared to
normal controls. Differences in PDE4B could not be con-
clusively determined because of the low expression level of
PDE4B in human heart. Reduced activity of PDE4 sub-
types is due to changes in protein levels as demonstrated
for PDE4D in Fig. 5d and e. This reduction in PDE4D
protein expression may be responsible for the reduced
levels of PDE4D associated with the RyR2 in failing
human hearts which was reported previously [39]. The
parallel downregulation of cardiac PDE4 in an animal
model of pathologic cardiac hypertrophy and in failing
human hearts suggests that changes in PDE4 levels may be
functionally significant in the development of heart failure.
PDE4 affects local but not global cAMP levels
in human cardiomyocytes
As PDE4 expression patterns and the assembly of macro-
molecular signaling complexes involving PDE4 appear
conserved among mice, rats and humans, we expected
inactivation of PDE4 to have similar effects in
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Fig. 4 Detection of macromolecular signaling complexes involving
PDE4 in the human heart. Detergent extracts prepared from human
failing myocardium were immunoprecipitated with normal IgG as a
control or with antibodies generated against a the b1-adrenergic
receptor (b1AR) or b phospholamban (PLB). PDE activity recovered
in the IP pellets was then measured in the absence or presence of the
PDE4-selective inhibitor rolipram (10 lM). All data are presented as
mean ± SEM of at least three experiments. Cyclic AMP-PDE
activity in PLB IPs was significantly greater compared to IgG control
using paired t test (#p \ 0.05), whereas the p value was 0.054 using
unpaired t test. **p \ 0.01 (unpaired t test)
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microdomains of cAMP signaling in all three species.
However, as inactivation of PDE4 removes only a small
fraction of the total cellular PDE activity in human heart but
a substantial amount of total cellular PDE activity in rodent
hearts (Fig. 1b), we expected PDE4 inhibition to affect
‘global’ cAMP signaling to a much greater degree in rodent
hearts. To test this, we studied the effect of PDE4 inhibition
on PKA-dependent phosphorylation patterns in dividing
human cardiomyocytes (DHCMs) in culture. These cells
exhibit a pattern of PDE subtypes similar to that of human
heart tissue (Fig. 6a), with PDE4 representing a minor
fraction of total PDE activity. In response to b-adrenergic
stimulation with isoproterenol (ISO), a large number of
proteins is phosphorylated by PKA as detected in immu-
noblots using a PKA substrate antibody (Fig. 6b). Pre-
treatment with the PDE4 inhibitor rolipram has no obvious
effect on PKA phosphorylation levels of the majority of
proteins, either under basal conditions or after ISO treat-
ment. This observation concurs with the idea of PDE4
having little impact on global cAMP signaling. However,
the phosphorylation of several individual PKA substrates
was increased upon PDE4 inhibition either under basal
conditions or after ISO stimulation as shown on the example
of the 135 and 20 kDa bands in Fig. 6b–d, respectively.
This confirms a role of PDE4 in regulating phosphorylation
of specific PKA substrates in human cardiomyocytes.
In contrast, in neonatal mouse cardiomyocytes, in which
PDE4 represents [50% of total cAMP-hydrolytic activity
[63], inhibition of PDE4 increased the level of phosphory-
lation of a large number of PKA substrates under basal
conditions and further potentiated PKA phosphorylation
levels induced by ISO (Fig. 6e, f). We were unable to
identify any bands of PKA substrates that were increased
by b-adrenergic stimulation without being increased by
treatment with rolipram or further elevated by combined
treatment with ISO and rolipram. The increased phos-
phorylation levels of this large number of bands suggest
that, in addition to specific microdomains of signaling,
PDE4 inactivation in mouse cardiomyocytes elevates
cAMP levels and PKA activity globally, thus, likely also
affecting compartments that are not specifically controlled
by localized PDE4.
Discussion
cAMP signaling in cardiac myocytes is compartmentalized
[43, 49]. Owing to differences in their intracellular
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localization, individual phosphodiesterases contribute to
this compartmentalization by regulating cAMP content,
and hence cAMP-dependent protein phosphorylation, in
individual compartments. As a corollary, the functional
significance of a particular PDE subtype is not solely
determined by its expression level in a given cell or tissue,
and PDE subtypes that represent a minor fraction of total
PDE activity might have important roles by acting locally
in critical microdomains of cAMP signaling. As a conse-
quence of this compartmentalization, not all cAMP pro-
duced is exposed to degradation by the total cellular
cAMP-PDE activity. Indeed, this is a prerequisite for
cAMP signaling to occur at similar, physiologically
effective concentrations even though total PDE activity is
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Fig. 6 Effect of PDE4
inactivation on phosphorylation
of PKA substrates in human and
mouse cardiomyocytes.
a Detergent extracts prepared
from dividing human
cardiomyocytes (DHCMs) in
culture were subjected to PDE
activity assays in the presence
or absence of PDE subtype-
selective inhibitors using a
substrate concentration of 1 lM
cAMP. Data represent the
average of three experiments.
Cultures of dividing human
cardiomyocytes (b–d) or mouse
neonatal cardiomyocytes
(e/f) were treated with or
without the PDE4 inhibitor
rolipram (10 lM) for 5 min
followed by a 5-min treatment
with isoproterenol (ISO; 1 lM).
Similar amounts of detergent
extracts prepared from these cell
cultures were separated by SDS/
PAGE and phosphorylation of
PKA substrates was
subsequently detected using a
PKA substrate-selective
antibody. b Representative
immunoblot of the PKA
phosphorylation pattern
in human cardiomyocytes.
c/d Immunoblots and
quantification of immunoblot
signal intensity for two PKA
substrates in human
cardiomyocytes that migrate at
135 kDa (c) and 20 kDa (d),
respectively. e/f Representative
Western blot and quantification
of PKA phosphorylation
patterns in neonatal mouse
cardiomyocytes. *p \ 0.05;
**p \ 0.01
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five times higher in human compared to rodent hearts
(Fig. 1), whereas cAMP production by adenylyl cyclases is
essentially the same (Supplementary Fig. 1).
Over the last decade, much progress has been made in
uncovering the functions of individual PDE4 variants in the
rodent heart [26]. The picture that has emerged is that
individual PDE4 variants localized to discreet microdo-
mains of cAMP signaling control the activity of individual
proteins such as bARs, Cav1.2, RyR2, and PLB/SERCA
within these domains [35, 39, 41, 58, 63, 84]. In addition,
PDE4 isoforms, cumulatively, may also control cAMP-
mediated signaling at a global level in cardiac myocytes.
However, with the exception of the RyR2/PDE4D complex,
the individual functions of PDE4s have not been confirmed
in human tissues, and the general applicability of observa-
tions made in rodents to humans has been uncertain because
of the observation that PDE4 inhibitors affect a large frac-
tion of the cAMP-hydrolytic activity in the hearts of mice
and rats (as well as other relevant animal models such as
dog) but only a minor fraction of the cAMP-hydrolytic
activity in human hearts (Fig. 1b) [1, 41, 46, 53, 63, 69, 79–
82]. The experiments described here address these issues.
We show that PDE4 activity is present in human hearts at
levels similar to those found in mouse and rat hearts (Fig. 1).
There is a strong conservation of expression patterns of
PDE4s among the three species with respect to subtypes and
splicing variants (Figs. 2, 3). Furthermore, in humans, PDE4
is tethered to macromolecular signaling complexes that are
known to involve the same enzymes in the rodent heart,
including the phospholamban/SERCA2 and the b1AR
complexes (Fig. 4). These findings suggest that PDE4 iso-
forms are likely to have roles in the local control of cAMP
signaling in human hearts that are similar to their roles in
rodent hearts. These results, when added to observations that
PDE4D binds RyR2 and controls the PKA-mediated phos-
phorylation of this channel in both mouse and human heart
[39] and that PDE4 regulates b-adrenoceptor-stimulated
L-type calcium channel currents (ICa) in rodent, rabbit, as
well as human cardiomyocytes [31, 35, 41], document the
roles of PDE4 isoforms in human as well as rodent hearts.
How PDE4 regulation of these signaling proteins impacts
contractility of human ventricular myocytes remains to be
determined at the mechanistic level. PDE4 inhibition has
been shown to produce a minor increase in inotropy in
human atrial trabeculae [74] and to potentiate serotonin-
stimulated inotropy in human left ventricular trabeculae
under concomitant inhibition of PDE3 [2] suggesting the
involvement of PDE4 variants in controlling excitation-
contraction coupling in humans as well as in rodents.
However, other studies did not detect an effect of PDE4
inhibition on the positive inotropic effects mediated through
5-HT4 receptors in human atrium and b1ARs and b2ARs in
human atrium as well as ventricle [6, 8, 14, 33].
Whereas PDE4 expression levels and patterns are sim-
ilar among mice, rats and humans, our findings also dem-
onstrate a major difference between rodent and human
hearts: while PDE4 accounts for 30–50% of the total
measured cAMP-hydrolytic activity in mouse and rat
hearts, it accounts for less than 10% of this activity in
human hearts, owing to the much higher levels of other
phosphodiesterases in the latter. This finding is in agree-
ment with prior studies showing that the vast majority of
cAMP-hydrolytic activity in human ventricular myocar-
dium is attributable to isoforms belonging to the PDE1,
PDE2 and PDE3 families [18, 59, 76]. This difference
between humans and rodents may have biological conse-
quences that are uncovered when PDE4 is inactivated, as
PDE4 isoforms, cumulatively, may also control cAMP-
mediated signaling at a global level in cardiac myocytes.
PDEs may contribute to the generation of cAMP com-
partments by acting as barriers for cAMP diffusion [30] or
as local sinks for cAMP [72]. One could, therefore, envi-
sion that the higher amount of PDE activity present in the
human heart would promote a tighter control of cAMP
compartmentalization. Since PDE4 represents the pre-
dominant fraction of total cAMP-hydrolytic activity in
rodent heart, its inhibition may limit PDE barrier function
and allow broad cAMP diffusion. In addition, it would
result in accumulation of a substantial amount of global
cAMP because the remaining non-PDE4s may not be able
to fully compensate for the loss of PDE4 activity. Indeed,
rolipram treatment has been reported to increase total
cAMP levels as measured by radioimmunoassay in neo-
natal mouse cardiac myocytes [84]. A similar effect of
PDE4 inhibition on total cAMP levels would not be
expected in human heart because of the large amount of
non-PDE4 activity, which could compensate for the loss of
PDE4 on the global scale. Indeed, by comparing the effects
of PDE4 inactivation on human and mouse cardiomyocytes
(Fig. 6), we observe that a plethora of PKA substrates is
hyper-phosphorylated upon PDE4 inhibition in mouse
cardiomyocytes, whereas only a limited number of PKA
phosphorylations is potentiated by PDE4 inhibition in
human cells. These distinct patterns of PKA phosphoryla-
tions are in line with the idea that PDE4 inactivation has
local effects on cAMP signaling in both species, whereas
global effects on cAMP signaling are evident only in
rodent cardiomyocytes (Fig. 7).
With the onset of cardiac disease, the cAMP signaling
cascade undergoes dramatic changes. Although catechol-
amine levels are high, the bAR/Gs protein/adenylyl cyclase
axis of cAMP production is downregulated and desensi-
tized [5, 44, 51]. Several studies have explored whether
reduction in cAMP production in diverse models of murine
cardiac disease are accompanied by changes in cAMP-
hydrolytic capacity. While there are some differences
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between disease models, the majority of studies investi-
gating this issue reported a downregulation of protein and
activity for different PDE subtypes including PDE4 [1, 12,
39, 47, 67, 70, 86]; see [57] for a review. The cause of
these changes is still poorly understood. According to one
hypothesis, the reduction in PDE activity may initially be
compensatory and aimed to increase cAMP levels and,
thus, cardiac output. However, the reduced cAMP-hydro-
lytic capacity may result in impairment of the tight regu-
lation of cAMP signaling and the separation of cAMP
compartments and, thus, may eventually contribute to
the development of heart disease. The significance of
controlling cAMP compartmentation is supported by the
observation that increases of cAMP levels by distinct
mechanisms can have opposing effects on cardiac function.
Stimulation of cAMP signaling through treatment with
b-adrenergic agonists or PDE3 inhibitors, although stimu-
lating contractility in the short term, results in increased
mortality in heart failure patients. Conversely, stimulation
of cAMP levels through overexpression of adenylyl
cyclase 6 (AC6) is cardioprotective in mice (see [23, 40],
for a review). In agreement with previous findings in a rat
model of cardiac hypertrophy [1], we report here that
PDE4A expression is reduced in failing human hearts
compared to normal controls (Fig. 5b). Transcripts and
promoter activity of PDE4A10, which we show to be the
major PDE4A variant expressed, are downregulated in
response to increased cAMP levels in mouse cardiomyo-
cytes [48]. This effect is PKA-dependent and driven by a
pool of cAMP that is generated by b-adrenoceptor stimu-
lation and controlled by PDE4-dependent cAMP hydro-
lysis. Thus, chronically high catecholamine levels, a
hallmark of heart failure, may contribute to the cAMP-
dependent downregulation of PDE4A in the hearts of both
rodents and humans in particular at the onset of cardiac
disease, at which point bAR-dependent cAMP stimulation
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Fig. 7 Illustration of the role of PDE4 in rodent and human
cardiomyocytes and the effect of PDE4 inhibition. A given subcel-
lular domain in rodent or human cardiac myocytes is indicated as a
large ellipse with its gray shading representing cAMP levels within
this domain. This subcellular domain contains several localized pools
of PDE4 as well as localized pools of non-PDE4 (PDEX) which are
more frequent in human cardiomyocytes due to the higher levels of
non-PDE4 expression compared to rodents (see Fig. 1). Localized
pools of PDEs deplete microdomains of signaling of cAMP, thus
acting as a sink for cAMP. These are indicated as small ellipses
beneath the PDE4/PDEX label and their lighter color illustrates the
reduced cAMP levels in these microdomains. Upon PDE4 inactiva-
tion, microdomains that had previously been depleted of cAMP by
PDE4 in human heart, now assume cAMP levels of their surrounding
environment (gray). In microdomains that had been controlled by
both PDE4 and non-PDE4, a partial effect of PDE4 inhibition could
be expected. The same effect occurs in principal in mouse cardiac
myocytes. However, as PDE4 inactivation has also removed a large
percentage of the total PDE activity, cAMP that was previously
degraded by PDE4 now accumulates in the cell resulting in higher
global cAMP levels indicated as the dark shading of the large ellipse.
Increase in global cAMP levels also affects cAMP signaling in
microdomains that are controlled by localized non-PDE4s (PDEX).
The degree to which this increase in global cAMP affects microdo-
mains controlled by non-PDE4s will depend on the amount of non-
PDE4 tethered to this compartment and whether negative feedback
mechanisms, such as a PKA-mediated activation of PDE3 [56], may
increase the activity of the localized non-PDE4 and thus counteract
exposure to increased global cAMP levels. The increase in global
cAMP levels due to PDE4 inhibition in rodent heart is not expected to
occur in the human heart, because the large amount of non-PDE4
remaining in the cell will compensate for the loss of PDE4
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is not yet desensitized. In agreement with the reduced
PDE4A levels we report, PDE4A mRNA has been shown
to be reduced in patients with non-ischemic cardiomyo-
pathy compared to non-failing hearts (GEO dataset
GDS1362 [36]). The mechanisms that control PDE4D
expression in the heart have not been explored thus far. It
was previously shown that the amount of PDE4D3 that is
associated with RyR2 is reduced in failing human hearts
compared to normal controls, and this change has been
proposed to contribute to dysregulation of RyR2 in heart
failure [39]. Our observation that PDE4D expression
levels are reduced in failing hearts (Fig. 5c–e) may sug-
gest that the reduced levels of PDE4D associated with
RyR2 in heart failure are due to lower cellular expression
levels of PDE4D rather than an altered interaction of
PDE4D with RyR2. However, it should be emphasized
that the extent to which changes in phosphodiesterase
levels contribute to the pathophysiology or represent
compensatory responses is unknown.
PDE4-selective inhibitors are currently being devel-
oped as therapeutic agents for inflammatory diseases
such as asthma and chronic obstructive pulmonary dis-
ease (COPD) to avoid the cardiovascular effects associ-
ated with broad-spectrum PDE inhibitors such as
theophylline [27]. The observation that PDE4 inactiva-
tion can trigger arrhythmias and lead to the development
of heart failure in mice raises the question of whether
PDE4 inhibitor treatment may represent a risk factor for
cardiac disease also in humans. Indeed, PKA-hyper-
phosphorylation of RyR2 as a result of reduced PDE4D
levels has been proposed to promote dysregulation of
this channel in both mice and humans [39]. The PDE4D
gene has also been associated with increased risk of
cardioembolic stroke in an Icelandic cohort [17],
although studies in non-Icelanders reported variable
results [55] and PDE4D in cells other than cardiomyo-
cytes may be responsible. However, a recent 1-year trial
with the PDE4 inhibitor roflumilast reported no differ-
ences in the incidence of most cardiovascular adverse
events in the PDE4 inhibitor and placebo group,
respectively, although atrial fibrillation was an infrequent
complication reported in higher numbers in the roflumi-
last group compared to controls [4]. The findings of the
present study suggest that PDE4 inhibition could affect
local signaling events, such as in macromolecular sig-
naling complexes that tether PDE4, similarly in both
rodents and humans, but affect global cAMP signaling
only in rodent heart. It is unknown whether dysregula-
tion of local signaling events or changes in global cAMP
signaling drive the adverse cardiac effects observed in
rodents. If the latter is the case, our findings might
explain why adverse cardiac effects reported for animals
have not been observed in humans.
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